Inflammasome
K (Der Seiteninhalt wurde durch einen anderen Text ersetzt: „{{up|PHA Biologicals}} {{qt|Colchicine}} {{ttp|p=32493814|t=2020. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.…“) |
|||
| Zeile 4: | Zeile 4: | ||
{{ttp|p=32493814|t=2020. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.|pdf=|usr=007}} | {{ttp|p=32493814|t=2020. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.|pdf=|usr=007}} | ||
{{tp|p=32574259|t=2020. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.|pdf=|usr=011}} | {{tp|p=32574259|t=2020. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.|pdf=|usr=011}} | ||
| + | {{tp|p=32655582|t=2020. Targeting the NLRP3 Inflammasome in Severe COVID-19.|pdf=|usr=015}} | ||
| + | {{tp|p=32670297|t=2020. Severe COVID-19: NLRP3 Inflammasome Dysregulated.|pdf=|usr=014}} | ||
| + | {{tp|p=32744716|t=2020. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential.|pdf=|usr=017}} | ||
| + | {{tp|p=32776354|t=2020. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing.|pdf=|usr=017}} | ||
| + | {{tp|p=32824985|t=2020. 4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor.|pdf=|usr=018}} | ||
| + | {{tp|p=32841451|t=2020. Targeting NLRP3 Inflammasome in an Animal Model for SARS-CoV-2.|pdf=|usr=018}} | ||
| + | {{tp|p=32965010|t=2020. SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?|pdf=|usr=019}} | ||
| + | {{tp|p=32980515|t=2020. Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor.|pdf=|usr=019}} | ||
| + | {{tp|p=33066442|t=2020. The Inhibition of NLRP3 Inflammasome and IL-6 Production by Hibiscus noldeae Baker f. Derived Constituents Provides a Link to Its Anti-Inflammatory Therapeutic Potentials.|pdf=|usr=021}} | ||
| + | {{tp|p=33099890|t=2020. COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?|pdf=|usr=020}} | ||
Aktuelle Version vom 11. April 2021, 20:22 Uhr
| PHA Biologicals |
| Colchicine |
| 32493814 2020. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19. |
32574259 2020. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.
32655582 2020. Targeting the NLRP3 Inflammasome in Severe COVID-19.
32670297 2020. Severe COVID-19: NLRP3 Inflammasome Dysregulated.
32744716 2020. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential.
32776354 2020. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing.
32824985 2020. 4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor.
32841451 2020. Targeting NLRP3 Inflammasome in an Animal Model for SARS-CoV-2.
32965010 2020. SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?
32980515 2020. Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor.
33066442 2020. The Inhibition of NLRP3 Inflammasome and IL-6 Production by Hibiscus noldeae Baker f. Derived Constituents Provides a Link to Its Anti-Inflammatory Therapeutic Potentials.
33099890 2020. COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?
